Body Mass Index (BMI) may affect how well aspirin use protects against colorectal and ovarian cancer
https://www.facingourrisk.org/XRAY/aspirin-may-protect-against-colorectal-and-ovarian-cancer
Full article: https://doi.org/10.1007/s10552-020-01357-2
This study looked at the impact of daily aspirin use on the risk for many types of cancers and whether this effect can be modified by risk factors such as obesity, smoking, physical inactivity or a family history of cancer. Daily aspirin use:
- lowered the risk for colorectal cancer, but this effect was lost as Body Mass Index (BMI) increased.
- lowered the risk of ovarian cancer risk among obese women.
- offered little or no protection against breast, endometrial or advanced prostate cancer.
(posted 3/19/21)
Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- How can I lower my risk for colorectal cancer, ovarian and other cancers?
- I have a family history of colorectal cancer, ovarian and other cancers; will daily aspirin use benefit me?
Open Clinical Trials
The following are studies looking at colorectal cancer screening or prevention.
- NCT04427527: Accelerating Colorectal Cancer Screening Through Implementation Science in Appalachia (ACCSIS). The goal of this study is to increase colorectal cancer screening in Appalachian Kentucky and Ohio.
- NCT03218423: Longitudinal Performance of Epi proColon (PERT). This study will evaluate a blood test for colorectal cancer.
- NCT04940442: Outreach and Choice in Colorectal Cancer Screening. This study will compare overall colorectal cancer (CRC) screening participation between fecal immunochemical test [FIT] and colonoscopy.
- NCT04379999: Atorvastatin ± Aspirin in Lynch Syndrome Syndrome. This study will investigate whether a common cholesterol-lowering agent (atorvastatin) alone or combined with a nonsteroidal anti-inflammatory drug (aspirin) reduces the risk of colorectal cancer (CRC) in high-risk individuals with Lynch syndrome.
-
NCT05078866: Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients. This study aims to see whether the Nous-209 cancer vaccine is safe to give to patients with Lynch syndrome. This study may help researchers determine whether receiving Nous-209 affects the development of polyps or tumors in the colon.
Other colorectal cancer screening and prevention studies may be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.